In addition, we demonstrated that GDF-15 outperformed other diagnostic biomarkers for mitochondrial diseases and postulated that it may also serve to monitor response to treatment based on preliminary data of one patient with TK2 deficiency that was treated with deoxynucleotides replacement therapy14,15. This evidence concerns the gene TK2 and hyperinsulinemic hypoglycemia, familial, 4.